Evidence-based clinical review Blood-Based Colorectal Cancer Screening in Family Practice: Where Shield Fits Among FIT, Stool DNA, and Colonoscopy A practical framework for average-risk adults who remain unscreened or decline preferred modalities Abstract Background: The U.S. Food
Oncology
Real-World Evidence vs Randomized Trials in Oncology: When Should Practice Change?
Multi-Cancer Early Detection Blood Tests in Family Practice: Clinical Promise, False Positives, and the Risks of Premature Adoption
Intratumoral Immunotherapy and In-Situ Vaccination: Local Shots, Systemic Responses?
ATR and WEE1 Inhibitors After PARP Resistance: Emerging DNA Damage Response Strategies Across Solid Tumors
ATR and WEE1 Inhibitors After PARP Resistance: Emerging DNA Damage Response Strategies Across Solid Tumors Review Abstract Background Resistance to poly(ADP-ribose) polymerase (PARP) inhibition has intensified interest in other components of the DNA damage response and replication-stress network. Early clinical studies have evaluated ataxia telangiectasia
Skin Cancer Detection and Procedural Decisions in Family Practice: When to Biopsy, Use Cryotherapy, or Refer
Skin Cancer Detection and Procedural Decisions in Family Practice: When to Biopsy, Use Cryotherapy, or Refer Review Abstract Background Evaluation of an identified suspicious skin lesion is fundamentally distinct from routine skin cancer screening. The U.S. Preventive Services Task Force (USPSTF) concludes that evidence is insufficient to
Melanoma Screening in the AI Era: Why Dermatologists Remain the Clinical Standard and AI Should Stay an Adjunct
Melanoma Screening in the AI Era: Why Dermatologists Remain the Clinical Standard and AI Should Stay an Adjunct Review Abstract Purpose: Melanoma remains one of the most aggressive forms of skin cancer, accounting for a disproportionate number of skin cancer related deaths despite representing a relatively small
BTK Degraders in CLL/SLL After BTK Inhibitor Failure: A Promising Escape Route Still Under Study
BTK Degraders in CLL/SLL After BTK Inhibitor Failure: A Promising Escape Route Still Under Study Review Abstract Purpose: This review assesses the rationale, emerging clinical evidence, safety considerations, and practical implications of Bruton tyrosine kinase (BTK) degraders in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), particularly after
Can Bispecific Antibodies Move Safely Into the Outpatient Clinic? A Label-Concordant Framework for Clinicians
Can Bispecific Antibodies Move Safely Into the Outpatient Clinic? A Label-Concordant Framework for Clinicians Review Abstract Purpose: This review assesses whether CD3-engaging bispecific antibody therapy can be delivered safely in outpatient oncology settings, with emphasis on cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infection prevention,
Menin Inhibitors in AML: Targeting KMT2A-Rearranged and NPM1-Mutated Disease
Menin Inhibitors in AML: Targeting KMT2A-Rearranged and NPM1-Mutated Disease Review Abstract Purpose Acute myeloid leukemia (AML) is a heterogeneous group of hematologic malignancies defined increasingly by recurrent molecular and cytogenetic abnormalities. KMT2A rearrangements and NPM1 mutations identify biologically distinct leukemias that frequently rely on menin-dependent
